Abstract
Aim: Congenital human CMV (HCMV) infection can lead to long-term neurodevelopmental sequelae, including mental retardation and sensorineural hearing loss. Preconception vaccine strategies relevant to the prevention of HCMV-mediated injury to the newborn can be studied in the Guinea pig CMV (GPCMV) model. The objectives of this study were: to assess in Guinea pigs the protective efficacy against congenital infection and disease of a recombinant live, attenuated vaccine with a targeted deletion of the GPCMV homolog of the HCMV pUL83 tegument protein, GP83; and to compare the extent of placental infection in vaccine and control groups using an in situ hybridization assay. Materials & methods: Outbred Hartley Guinea pigs were vaccinated prior to pregnancy with a two-dose series of 5 × 104 PFU of vAM409, a GP83 deletion virus. Deletion of the GP83 gene resulted in an attenuated virus, and vAM409-vaccinated animals did not demonstrate evidence of DNAemia following vaccination, although ELISA antibody responses ...
Funding Information
  • National Institutes of Health (R01HD044864, R01HD038416)

This publication has 38 references indexed in Scilit: